SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-24-268973 from Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions Inc.
Date: Dec. 2, 2024 · CIK: 0001367644 · Accession: 0001193125-24-268973

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-283150

Date
December 2, 2024
Author
By
Form
CORRESP
Company
Emergent BioSolutions Inc.

Letter

Re: Emergent BioSolutions Inc.

December 2, 2024

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1

File No. 333-283150

Filed November 12, 2024

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Emergent BioSolutions Inc. hereby respectfully requests that the effective date for the above-referenced registration statement be accelerated to 4:00 p.m., Eastern Time, on December 4, 2024, or as soon as practicable thereafter.

Should you have any questions or comments regarding the foregoing, please contact Matthew C. Franker or Julie M. Plyler of Covington & Burling LLP at (202) 662-5895 or (212) 841-1090, respectively.

Respectfully,
Emergent BioSolutions Inc.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 December 2, 2024

Via EDGAR

 U.S. Securities and Exchange Commission

Division of Corporation Finance

 100 F Street, N.E.

Washington, D.C. 20549

Re:
 Emergent BioSolutions Inc.

Registration Statement on Form S-1

File No. 333-283150

Filed November 12, 2024

 Ladies and
Gentlemen:

 Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Emergent BioSolutions Inc. hereby respectfully requests
that the effective date for the above-referenced registration statement be accelerated to 4:00 p.m., Eastern Time, on December 4, 2024, or as soon as practicable thereafter.

Should you have any questions or comments regarding the foregoing, please contact Matthew C. Franker or Julie M. Plyler of
Covington & Burling LLP at (202) 662-5895 or (212) 841-1090, respectively.

Respectfully,

Emergent BioSolutions Inc.

By:

/s/ Jessica Perl

Name:

Jessica Perl

Title:

Senior Vice President, General Counsel and Corporate Secretary

cc:
 Tamika Sheppard

Matthew C. Franker

 Julie M.
Plyler